Lung cancer is the malignant tumor with the highest morbidity and mortality in China. Non-small cell lung cancer (NSCLC) is the main pathological subtype of lung cancer. On April 13, 2023, the National Comprehensive Cancer Network (NCCN) released the third edition of the 2023 NCCN Oncology Clinical Practice Guidelines: Non-small Cell Lung Cancer, which reflects the latest advances in international lung cancer research. This article will interpret the main updated contents of the new edition of the guidelines, and compare it with the third edition of the NCCN guidelines in 2022, so as to provide references about the diagnosis and treatment of NSCLC for clinical medical personnel in China. .
【中文题目：2023年第3版《NCCN肿瘤临床实践指南：非小细胞肺癌》更新解读】 【中文摘要：肺癌是我国发病率和死亡率均居首位的恶性肿瘤，非小细胞肺癌（non-small cell lung cancer, NSCLC）是肺癌的主要病理学亚型。2023年4月13日，美国国立综合癌症网络（National Comprehensive Cancer Network, NCCN）发布了2023年第3版《NCCN肿瘤临床实践指南：非小细胞肺癌》，其反映了国际肺癌研究的最新进展。本文将对新版《指南》主要更新内容进行解读，并与2022年第3版NCCN指南相比较，旨在为我国临床医务人员诊治NSCLC提供参考。 】 【中文关键词：临床实践；肺肿瘤；NCCN指南；指南解读；循证医学证据】.
Keywords: Clinical practice; Evidence-based medicine; Guideline interpretation; Lung neoplasms; NCCN guideline.